Barely Significant
← all excerpts

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis.

Ann Allergy Asthma Immunol · 2022 · PMC8956356 · PMID 35346880

Europe PMCDOI
1
hedged sentence
0.0900
closest p · 1.8× alpha
0.0900
boldest claim

The sentences

approaching significanceP = .09so close (0.05 < p ≤ 0.1)
Overall, this study found that patients had significantly lower antibody levels after COVID-19 infection when treated with dupilumab vs systemic therapies ( P = .01), and lower levels (approaching significance, P = .09) compared with patients receiving limited/no therapy, paralleling our previous finding that dupilumab-treated patients were more likely to have milder symptoms COVID-19 symptoms compared with patients on broad-acting treatments and also those receiving limited/no treatment. 1 However, there were no differences in antibody levels among treatment groups after mRNA vaccination.

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.